Form 4: Illumina CEO Jacob Thaysen Increases Stake in Company with Recent Stock Purchases

Illumina's CEO, Jacob Thaysen, has recently acquired additional shares of the company's common stock through a series of transactions.

Summary

• On May 12th and 13th, 2025, Jacob Thaysen, the CEO of Illumina, purchased shares of the company's common stock.
• The purchases were made at varying prices, ranging from $79.27 to $82.93 per share.
• The total number of shares acquired across these transactions was 12,350.
• Following these transactions, Thaysen directly owns 83,390 shares of Illumina common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the CEO's stock purchase suggests confidence in the company's future, but it's a routine transaction.

Positives

• The CEO's purchase of company stock could be interpreted as a sign of confidence in Illumina's future prospects.

Industry Context

Insider buying is often seen as a positive signal, suggesting that a company's leadership believes the stock is undervalued. It's a common practice among executives and board members.

Comparison to Industry Standards

• Comparing Jacob Thaysen's purchases to other CEO stock acquisitions in the biotech industry, the size of the purchase is moderate.
• For example, the CEO of Regeneron, Leonard Schleifer, has made larger purchases of his company's stock in the past.
• However, Thaysen's purchases are similar in scale to those made by CEOs of smaller biotech firms.

Stakeholder Impact

• Shareholders may view the CEO's stock purchase as a positive signal.

Key Dates

Keywords

Illumina, ILMN, Jacob Thaysen, stock purchase, CEO, Form 4, insider trading